Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Background and study aims
Bo-Er-Ning capsule (BENC) is a traditional Chinese medicine derived from natural products. It is composed of a series of key pharmaceutical ingredients, including Radix Astragali, Fructus Ligustri Lucidi, Tulipaedulis, Herba Portulacae, Rhizoma Paridis , Solanum Nigrum, Fructus Perillae, Corium Stomachichum galli, Rhubarb, Borneol and Bombyx Batryticatus. The aim of this study is to assess the effect of BENC on gastric (stomach) cancer patients.

Who can participate?
Patients aged 25 to 75 with gastric cancer

What does the study involve?
Participants are randomly allocated into two groups: the trial group and the control group. The trial group receive BENC accompanying tegafur and cisplatin drug treatment, while the control group receive tegafur and cisplatin only. Both groups are assessed after three cycles of treatment (each cycle involves 14 days of treatment and 7 days of rest).

What are the possible benefits and risks of participating?
Patients from the trial group may have a better quality of life, such as better appetite and body weight gain, and improved overall survival. As a typical Chinese herb medicine, BENC has been used as an additional medicine for other types of cancer, and no side effects have been reported.

Where is the study run from?
Zhangqiu People's Hospital of Shandong (China)

When is the study starting and how long is it expected to run for?
January 2008 to June 2012

Who is funding the study?
Zhangqiu People's Hospital of Shandong (China)

Who is the main contact?
Prof. Jie He

Trial website

Contact information



Primary contact

Prof Jie He


Contact details

Zhangqiu People's Hospital of Shandong

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Evaluation of the adjuvant therapeutic efficacy of Bo-Er-Ning capsule (BENC) in advanced gastric cancer patients by a randomized clinical trial


Study hypothesis

The addition of BENC to chemotherapy is better than chemotherapy alone.

Ethics approval

Ethics board of Zhangqiu People's Hospital of Shandong, 04/03/2008, ref: ZQH/2008/03-1

Study design

Single-centre randomized controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet


Advanced gastric cancer


All patients with advanced GC treated by FP regimen (Tegafur + Cisplatin) in Zhangqiu People's Hospital of Shandong were enrolled for this clinical study by a doctor participating in the study and randomly divided into two groups by another doctor. Among those, 58 patients received BENC accompanying FP regimen (trial group), while 54 patients received FP regimen alone (control group).

Treatment regimen for control group: Tegafur 40~60mg, oral administration, two times a day, from day 1 to day 14 and Cisplatin 40mg, intravenous infusion administration, from day 1 to day 3.

Treatment regimen for trial group: BENC 4 capsules, taken orally three times a day (with warm water half an hour after a meal) for 14 days (from day 1 to day 14), accompanying Tegafur and Cisplatin treatment (the same drug dosage and usage as the control group).

Both groups were evaluated after 3 cycles (both groups take 21 days as one cycle) of chemotherapy (14 days of treatment and 7 days of rest).

Intervention type



Not Applicable

Drug names

Tegafur, cisplatin, Bo-Er-Ning capsule

Primary outcome measure

Measured at week 9 (after 3 cycles of chemotherapy):
1. Appetite, assessed by filling out answer sheets
2. Karnofsky performance score (KPS), assessed by filling out answer sheets
3. Body weight, measured using a weight scale

Secondary outcome measures

3-year overall survival: patients followed up by clinic visit, phone, or mail at least once every 6 months starting from day 1 after the treatment

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Age from 25 to 75 years
2. All patients were pathologically confirmed for stage IV or postoperative recurrence and metastasis GC
3. Karnofsky performance score (KPS) ≥ 80
4. No previous anticancer therapy
5. No dysfunction of heart, liver, lung and kidney

Participant type


Age group




Target number of participants

Trial group: 60; control group: 60

Participant exclusion criteria

1. Age<25 and >75 years
2. Patients were not pathologically confirmed for stage IV or postoperative recurrence and metastasis GC
3. Karnofsky performance score (KPS) < 80
4. Possess previous anticancer therapy
5. Possess dysfunction of heart, liver, lung and kidney

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Zhangqiu People's Hospital of Shandong

Sponsor information


Zhangqiu People's Hospital of Shandong

Sponsor details

1920 Huiquan Road
Zhangqiu District

Sponsor type

Hospital/treatment centre



Funder type

Hospital/treatment centre

Funder name

Zhangqiu People's Hospital of Shandong

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer reviewed journal.

IPD sharing statement
The datasets generated during and/or analysed during the current study are not expected to be made available to protect the privacy of the patients.

Intention to publish date

Participant level data

Not expected to be available

Basic results (scientific)

Publication list

2018 results in:

Publication citations

Additional files

Editorial Notes

17/01/2019: Publication reference added.